Nutriband to Present AVERSA Technology at MicroCap Rodeo Conference

Nutriband Inc. will participate in the MicroCap Rodeo Conference in New York City on September 25, 2025, where Company Chairman Serguei Melnik will present the company's operational highlights and strategic direction. The presentation, scheduled for 10 a.m., will focus on the development of the AVERSA platform technology and the company's growth initiatives in the pharmaceutical sector. The conference presentation provides investors and industry observers with insight into Nutriband's approach to addressing the critical issue of drug abuse prevention.

The company's lead product under development is an abuse-deterrent fentanyl patch that incorporates the AVERSA technology, designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This technology represents a significant advancement in transdermal drug delivery systems with built-in safety features. According to the press release available at https://ibn.fm/gMG2M, the AVERSA technology can be incorporated into any transdermal patch, potentially expanding its application beyond fentanyl to other drugs with abuse potential.

Interested parties can access the presentation through a live webcast, with registration available for those unable to attend in person. The company maintains its corporate information and updates through its official website at https://www.nutriband.com, where investors can find additional details about the company's pharmaceutical development portfolio. Additional news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB, providing ongoing information about the company's progress in developing abuse-deterrent pharmaceutical products.

The timing of this presentation comes as the pharmaceutical industry continues to address the ongoing opioid crisis and the need for safer drug delivery systems. Nutriband's participation in the MicroCap Rodeo Conference signals the company's commitment to engaging with the investment community about its technology platform and growth strategy. The conference presentation represents an important opportunity for Nutriband to communicate its strategic vision to potential investors and industry stakeholders.

As the company continues development of its AVERSA technology platform, this public presentation allows for greater transparency regarding the company's direction and the potential impact of its abuse-deterrent technology on pharmaceutical safety standards. The webcast availability ensures broader access to this information beyond those attending the conference in person. This presentation matters because it showcases a technological approach to a critical public health issue while demonstrating how emerging pharmaceutical companies are seeking investment to advance safety innovations in drug delivery systems.